Differential effects of simvastatin and bezafibrate on apolipoprotein-defined high-density lipoprotein subfractions in patients with hypercholesterolemia

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 1, 1996, Pages 26-32

  Branchi, Adriana ^a,c   Rovellini, Angelo ^a   Sommariva, Domenico ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b Bollate Hospital   (Italy)

^c Ist Med Int Fisiopatol Medica U   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; BEZAFIBRATE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIET; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK; SUSTAINED RELEASE PREPARATION;

EID: 0030069434     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80026-9     Document Type: Article

References (20)

1. Cheung MC, Albers JJ. Characterization of lipoprotein particles isolated by immunoaffinity chromatography: Particles containing A-I and A-II and particles containing A-I but not A-II. J Biol Chem. 1984;259:12201-12209.
2. Fruchart JC, Ailhaud G. Apolipoprotein A-containing particles: Physiological role, quantification and clinical significance. Clin Chem. 1992;38:793-797.
3. Moulin P, Cheung MC, Bruce C, et al. Gender effects on the distribution of the cholesteryl ester transfer protein in apolipoprotein A-I defined lipoprotein subpopulations. J Lipid Res. 1994;35:793-802.
4. Puchois P, Kandoussi P, Fievet P, et al. Apolipoprotein A-I containing lipoproteins in coronary artery disease. Atherosclerosis. 1987;68:35-40.
5. Genest JJ, Bard JM, Fruchart JC, et al. Plasma apolipoproteins A-I, A-II, B, E, C-III-containing particles in men with premature coronary artery disease. Atherosclerosis. 1991;90:149-157.
6. Cheung MC, Brown MG, Wolf A, Albers JJ. Altered particle size distribution of apolipoprotein A-I containing lipoproteins in subjects with coronary artery disease. J Lipid Res. 1991;32:383-394.
7. Atmeh RF, Shepard J, Packard CJ. Subpopulations of apolipoprotein A-I in human high density lipoproteins: Their metabolic properties and response to drug therapy. Biochim Biophys Acta. 1983;751:175-188.
8. Bard JM, Luc G, Douste-Blazy P, et al. Effect of simvastatin on plasma lipids, apolipoproteins and lipoprotein particles in patients with primary hypercholesterolemia. Eur J Clin Pharmacol. 1989;37:545-550.
9. Bard JM, Parra HJ, Luc G, et al. Lipoprotein particle analysis comparing simvastatin and fenofibrate. Atherosclerosis. 1991;91:S29-S34.
10. Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis. 1993;102:107-119.
11. Kahri J, Vuorinen-Markkola H, Tilly-Kiesi M, et al. Effect of gemfibrozil on high density lipoprotein subspecies in non-insulin dependent diabetes mellitus. Relations to lipolytic enzymes and to cholesteryl ester transfer protein activity. Atherosclerosis. 1993;102:79-89.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA. 1993;16:3015-3023.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Silverman DI, Ginsburg GS, Pasternak RC. High density lipoprotein subfractions. Am J Med. 1993;94:636-645.
15. Monk JP, Todd PA. Bezafibrate. A review. Drugs. 1987;33:539-576.
16. Barbaras R, Purchois P, Fruchart JC, Ailhaud G. Cholesterol efflux from cultured adipose cells is mediated by LpA-I particles but not by LpA-I:A-II particles. Biochem Biophys Res Commun. 1987;142:63-70.
17. Johnson WJ, Kilsdonk EPC, van Tol A, et al. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LpA-I and LpA-I/A-II. J Lipid Res. 1991;32:1992-2000.
18. Montali A, Vega GL, Grundy SM. Concentrations of apolipoprotein A-I containing particles in patients with hypoalphalipoproteinemia. Arterioscler Thromb. 1994;14:511-517.
19. Oikawa S, Mendez AJ, Oram JF, et al. Effects of high-density lipoprotein particles containing apo A-I with or without apo A-II on intracellular cholesterol efflux. Biochim Biophys Acta. 1993;1165:327-334.
20. Vadiveloo PK, Allan CM, Murray BJ, Fidge NH. Interaction of apolipoprotein A-II with the putative high density lipoprotein receptor. Biochemistry. 1993;32:9480-9485.